CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
Year in review: A look at events in May 2024
Long-term care homes in Ontario must have sprinkler systems installed by the end of this year and at least two announce they ...